Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Hawthorne, New York Clinical Trials

A listing of Hawthorne, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (423) clinical trials

A Study of Melflufen in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients

Melflufen is designed for targeted delivery of alkylating moieties to tumor cells. In contrast to other alkylating agents that are hydrophilic, the lipophilicity of melflufen leads to rapid and extensive distribution into tissues and cells. Inside cells, melflufen may directly bind DNA or is readily metabolized by intracellular peptidases into ...

Phase

0.0 miles

Learn More »

Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer

The purpose of this study is to evaluate the clinical benefit and safety of Apatinib plus Best Supportive Care in comparison to Placebo plus Best Supportive Care in patients with advanced or metastatic gastric cancer

Phase

0.0 miles

Learn More »

A Study of ASP2215 (Gilteritinib) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Subjects in CR1 will be approached for this study after induction/consolidation therapy is complete and a decision not to proceed with transplantation is made or a suitable donor could not be identified. Subjects will be randomized in a 2:1 ratio to receive gilteritinib or placebo. Subjects will enter the screening ...

Phase

0.0 miles

Learn More »

Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis

This randomized, double-blind, vehicle-controlled, parallel-group multiple-site study is designed to evaluate the therapeutic efficacy and safety of the investigational product, DSXS 1535 product, for the treatment of mild to severe scalp psoriasis

Phase

0.0 miles

Learn More »

An Open Label Safety Study to Assess the Potential for Adrenal Suppression.

To evaluate the potential of DSXS topical product to suppress HPA axis function in patients with moderate to severe atopic dermatitis.

Phase

0.0 miles

Learn More »

Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product

Evaluate the potential of DSXS topical product to suppress HPA axis function in patients with moderate to severe scalp psoriasis. Evaluate the efficacy parameters and adverse event (AE) profiles of DSXS topical product administered to patients with moderate to severe scalp psoriasis.

Phase

0.0 miles

Learn More »

Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS

Evaluate the potential of DSXS topical product to suppress HPA axis function in patients with moderate to severe scalp psoriasis. Evaluate the efficacy parameters and adverse event (AE) profiles of DSXS topical product administered to patients with moderate to severe scalp psoriasis.

Phase

0.0 miles

Learn More »

An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG

The registry is being conducted in an effort to better understand rates, risk factors, and outcomes associated with vascular occlusive events in patients treated with Iclusig (ponatinib) in real world settings. This registry study will collect information about patient demographics, leukemia diagnosis, previous anti-cancer treatments, history of cardiovascular disease, risk ...

Phase N/A

0.0 miles

Learn More »

Alvocidib Biomarker-driven Phase 2 AML Study

In Stage 1 of the study, all eligible AML patients with demonstrated NOXA BH3 priming of 40% by mitochondrial profiling in bone marrow will receive treatment with alvocidib, cytarabine and mitoxantrone [ACM ('FLAM') regimen]. In Stage 2, all eligible AML patients with demonstrated NOXA BH3 priming of 40% by mitochondrial ...

Phase

0.0 miles

Learn More »

Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)

Vasovagal syncope (VVS, simple faint) is the most common cause of transient loss of consciousness and represents the acute episodic form of orthostatic intolerance (OI). Postural tachycardia syndrome (POTS) is the common chronic form of OI. Both are defined by debilitating symptoms and signs while upright relieved by recumbency. Pathophysiological ...

Phase

0.0 miles

Learn More »